MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$52,149K
Net Income
$31,712K
Net Profit Margin
60.81%
EPS
$1.46
Unit: Thousand (K) dollars
Revenue Breakdown
Affitech Research As-Vabysmo
Tovorafenib-Viracta Therapeutics...
Revenue from contracts with cust...
Others
Revenue Breakdown
CH
US
Asia Pacific
AU
Subscribe for Financial Insights
Page 1
Annual
123
Page 1
Income Statement
2025-12-31
Total income and revenues
52,149
Research and development
1,712
General and administrative
36,092
Amortization of intangible assets
2,961
Total operating expenses
40,765
Income (loss) from operations
11,384
Gains on acquisitions
21,224
Interest expense
13,031
Other income, net
12,238
Net income (loss) before tax
31,815
U.s. federal statutory tax rate
6,681
Foreign tax effects
103
Changes in valuation allowances
-2,538
Stock based compensation
-584
Nondeductible executive compensation
735
Bargain purchase gain
4,457
Other permanent differences
163
Income tax (expense) benefit
103
Net income (loss)
31,712
Basic EPS
1.53
Diluted EPS
1.46
Basic Average Shares
12,081,000
Diluted Average Shares
17,982,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS).
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
Affitech Research
As-Vabysmo
$23,957K
Ladrx-Miplyffa
$1,799K
Aptevo-Ixinity
$989K
Tovorafenib-Viracta Therapeutics
Inc.
$13,716K
Dsuvia-Talphera
$28K
Income from purchased
receivables under the eir...
$26,745K
Income from purchased
receivables under the cost...
$13,744K
Revenue from contracts
with customers
$10,350K
Revenue recognized
under...
$1,310K
Total income and
revenues
$52,149K
Gains on acquisitions
$21,224K
Other income, net
$12,238K
Income (loss) from
operations
$11,384K
Total operating
expenses
$40,765K
Net income (loss)
before tax
$31,815K
Interest expense
$13,031K
General and
administrative
$36,092K
Amortization of intangible
assets
$2,961K
Research and development
$1,712K
Net income (loss)
$31,712K
Income tax (expense)
benefit
$103K
Bargain purchase gain
$4,457K
Changes in valuation
allowances
-$2,538K
Stock based
compensation
-$584K
U.s. federal
statutory tax rate
$6,681K
Nondeductible executive
compensation
$735K
Other permanent
differences
$163K
Foreign tax effects
$103K
Buy us a coffee
XOMA Royalty Corp (XOMAO)
XOMA Royalty Corp (XOMAO)